Rocket Pharmaceuticals (RCKT) Competitors

Rocket Pharmaceuticals (NASDAQ:RCKT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.

Does the MarketBeat Community favor RCKT or MRUS?

Rocket Pharmaceuticals received 38 more outperform votes than Merus when rated by MarketBeat users. Likewise, 73.59% of users gave Rocket Pharmaceuticals an outperform vote while only 67.90% of users gave Merus an outperform vote.

Company	Underperform	Outperform
Rocket Pharmaceuticals	Outperform Votes 404 73.59%	Underperform Votes 145 26.41%
Merus	Outperform Votes 366 67.90%	Underperform Votes 173 32.10%

Is RCKT or MRUS more profitable?

Rocket Pharmaceuticals has a net margin of 0.00% compared to Merus' net margin of -680.61%. Merus' return on equity of -38.89% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-62.62%	-54.17%
Merus	-680.61%	-38.89%	-31.16%

Which has preferable valuation and earnings, RCKT or MRUS?

Merus has higher revenue and earnings than Rocket Pharmaceuticals. Merus is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$245.60M	-$2.63	-2.51
Merus	$54.73M	54.64	-$154.94M	-$4.08	-10.59

Which has more volatility and risk, RCKT or MRUS?

Rocket Pharmaceuticals has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Merus has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in RCKT or MRUS?

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media prefer RCKT or MRUS?

In the previous week, Rocket Pharmaceuticals had 7 more articles in the media than Merus. MarketBeat recorded 24 mentions for Rocket Pharmaceuticals and 17 mentions for Merus. Merus' average media sentiment score of 0.96 beat Rocket Pharmaceuticals' score of 0.89 indicating that Merus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Merus	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer RCKT or MRUS?

Rocket Pharmaceuticals presently has a consensus price target of $37.73, indicating a potential upside of 472.49%. Merus has a consensus price target of $84.54, indicating a potential upside of 95.65%. Given Rocket Pharmaceuticals' higher possible upside, equities research analysts plainly believe Rocket Pharmaceuticals is more favorable than Merus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Merus	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.13

Summary

Rocket Pharmaceuticals beats Merus on 10 of the 18 factors compared between the two stocks.